Cargando…

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels in cerebrospinal fluid inversely correlated to psychotic symptoms. Furthermor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leweke, F M, Piomelli, D, Pahlisch, F, Muhl, D, Gerth, C W, Hoyer, C, Klosterkötter, J, Hellmich, M, Koethe, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316151/ https://www.ncbi.nlm.nih.gov/pubmed/22832859 http://dx.doi.org/10.1038/tp.2012.15

Ejemplares similares

Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
por: Leweke, F. Markus, et al.
Publicado: (2021)

Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid
por: Koethe, Dagmar, et al.
Publicado: (2009)

Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state
por: Koethe, Dagmar, et al.
Publicado: (2023)

Simultaneous Assessment of Serum Levels and Pharmacologic Effects of Cannabinoids on Endocannabinoids and N-Acylethanolamines by Liquid Chromatography–Tandem Mass Spectrometry
por: Couttas, Timothy A., et al.
Publicado: (2023)

Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers
por: Woelfl, Timo, et al.
Publicado: (2020)

Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
por: Bartoli, Francesco, et al.
Publicado: (2021)

CSF Metabolic and Proteomic Profiles in Patients Prodromal for Psychosis
por: Huang, Jeffrey T.-J., et al.
Publicado: (2007)

Enhancement of Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social Impairment
por: Wei, Don, et al.
Publicado: (2016)

Metabolic Profiling of CSF: Evidence That Early Intervention May Impact on Disease Progression and Outcome in Schizophrenia
por: Holmes, Elaine, et al.
Publicado: (2006)

Role of FAAH-Like Anandamide Transporter in Anandamide Inactivation
por: Leung, KwanNok, et al.
Publicado: (2013)

Schizophrenia-Like Psychotic Symptoms Associated to Leigh Syndrome
por: Jaballah, F., et al.
Publicado: (2023)

Speech-on-speech masking and psychotic symptoms in schizophrenia
por: Wu, Chao, et al.
Publicado: (2018)

Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
por: Rohleder, Cathrin, et al.
Publicado: (2016)

Vaccenic acid suppresses intestinal inflammation by increasing anandamide and related N-acylethanolamines in the JCR:LA-cp rat
por: Jacome-Sosa, Miriam, et al.
Publicado: (2016)

Arcuate Fasciculus Abnormalities and Their Relationship with Psychotic Symptoms in Schizophrenia
por: Abdul-Rahman, Muhammad Farid, et al.
Publicado: (2012)

Negative symptoms of schizophrenia in patients with acute and transient psychotic disorders
por: Aleshkina, G., et al.
Publicado: (2021)

Brain volume in chronic ketamine users — relationship to sub-threshold psychotic symptoms and relevance to schizophrenia
por: Chesters, Robert A., et al.
Publicado: (2021)

The Role of the Endocannabinoids 2-AG and Anandamide in Clinical Symptoms and Treatment Outcome in Veterans with PTSD
por: Leen, N.A., et al.
Publicado: (2022)

Childhood trauma in schizophrenia spectrum disorders and intensity of psychotic symptoms
por: Alvarez, M.-J., et al.
Publicado: (2021)

A catalytically silent FAAH-1 variant drives anandamide transport in neurons
por: Fu, Jin, et al.
Publicado: (2011)

Schizophrenia and psychotic symptoms in families of two American Indian tribes
por: Robin, Robert W, et al.
Publicado: (2007)

S248. RELATION BETWEEN CHILDHOOD TRAUMA AND PSYCHOTIC SYMPTOMS IN SCHIZOPHRENIA
por: Larnaout, Amine, et al.
Publicado: (2018)

Successful treatment of nightmares may reduce psychotic symptoms in schizophrenia
por: Seeman, Mary V
Publicado: (2018)

Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia
por: Iasevoli, Felice, et al.
Publicado: (2021)

Corticosteroid induced mania with psychotic symptoms
por: Tavares, F. Gomes, et al.
Publicado: (2021)

Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder
por: Hua, Daniel Ying-Heng, et al.
Publicado: (2023)

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
por: García-Gutiérrez, María S., et al.
Publicado: (2020)

Identification and recombinant expression of anandamide hydrolyzing enzyme from Dictyostelium discoideum
por: Neelamegan, Dhamodharan, et al.
Publicado: (2012)

Cannabidiol markedly alleviates skin and liver fibrosis
por: del Río, Carmen, et al.
Publicado: (2022)

Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid
por: Servadio, M, et al.
Publicado: (2016)

Multivariate Analysis of Relationship between Childhood Trauma and Psychotic Symptoms in Patients with Schizophrenia
por: Chae, Sungun, et al.
Publicado: (2015)

Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms
por: Lee, Jung Suk, et al.
Publicado: (2020)

Effects of Psychotic Symptoms and Social Cognition on Job Retention in Patients with Schizophrenia in Korea
por: Han, Mihwa, et al.
Publicado: (2020)

Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer’s disease
por: Creese, Byron, et al.
Publicado: (2019)

Impact of Negative Symptoms on Functioning and Quality of Life in First Psychotic Episodes of Schizophrenia
por: García-Fernández, Lorena, et al.
Publicado: (2022)

Case report: Impact of hyperthyroidism on psychotic symptoms in schizophrenia comorbid with Graves’ disease
por: Sumi, Yukiyoshi, et al.
Publicado: (2023)

High-Fat Diet-Induced Insulin Resistance Does Not Increase Plasma Anandamide Levels or Potentiate Anandamide Insulinotropic Effect in Isolated Canine Islets
por: Woolcott, Orison O., et al.
Publicado: (2015)

Childhood trauma, psychotic symptoms: which association?
por: Syrine, A., et al.
Publicado: (2023)

Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures
por: Malek, Natalia, et al.
Publicado: (2015)

Corrections: High-Fat Diet-Induced Insulin Resistance does not Increase Plasma Anandamide Levels or Potentiate Anandamide Insulinotropic Effect in Isolated Canine Islets
por: Woolcott, Orison O., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q235p99spjlusmpjf78rikkb9g